about
Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial OutcomesProstate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era.Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.Functional interference clusters in cancer patients with bone metastases: a secondary analysis of RTOG 9714.Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection.An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactionsEconomic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases.Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond.Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.NCCN clinical practice guidelines in oncology: prostate cancer.Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.Radiation medicine innovations for the new millenium.The evolving role of pelvic radiation therapy.Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long?Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer.High-risk prostate cancer-classification and therapy.Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancer.Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative.Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions.Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.Megavoltage cone-beam CT: system description and clinical applications.Radiotherapy in the management of common genitourinary malignancies.Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?Radiation dose-volume effects and the penile bulb.Goserelin acetate in combination with radiotherapy for prostate cancer.State-of-the-art radiotherapy in the management of clinically localized prostate carcinoma.Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy.New Clinical and Research Programs in Particle Beam Radiation Therapy: The University of California San Francisco Perspective.Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610.Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer.Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application.Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.
P50
Q27320007-69579C64-D14B-457B-BAE1-10E3856B6DD4Q31011194-D0BF2F9B-1774-48FE-ADD6-A67C2A1AE3A2Q33322056-0B71567F-F580-425A-B514-8874EC4508FDQ33756061-A30808FA-1EB3-412F-B718-CCCC1FE15227Q34017719-25F4F73A-62F6-4DFF-A081-8DEFF28B6F2FQ34048630-56A4A99D-B68D-4B36-85CE-26C3D7A782A7Q34138298-7E45D77F-9AE1-46BC-9126-77A785BD941DQ34187079-CF40E73C-F9E4-4C8A-8CC1-5321F0F33F0DQ34401982-E202716E-3593-4BA5-BC83-3A5082FCE009Q34541651-A0BA7DCC-60FE-40FD-BEBA-3834BC395D86Q34616548-37AC9F91-77BD-40C2-A5B9-3E85512A0982Q34683994-E7BD1F97-BFFA-4898-9A12-CBF3BDC1D944Q35006946-AA9B3E54-EDF1-4156-A977-DED444D703F1Q35091845-AE024441-CB3D-4B40-8AD4-41A15E4D859FQ35120279-4A61A956-2DD1-4E45-AA19-E1A76B953206Q35580979-F254230A-7C7A-404E-83FA-FA6A015CEF03Q35580987-7EDA04FF-88CF-4445-A0EF-BE28890B72DCQ35763115-FE91616C-0E8D-436C-B99D-1B0211363210Q35869811-739DA0A2-4583-4AD9-AC86-248EA0188C3CQ35992601-E4B85470-B9AB-463D-9D08-3B164FF8BA46Q36059968-5E626994-FD7C-466B-ADBF-2EF6F499C083Q36105848-CC76D6C0-B730-44CC-9A35-4987D2B5A985Q36267008-5564DFB0-91F5-40B1-B05A-4E6A772F1403Q36309685-1402EEA6-FD8F-495B-9D78-C765A507D0C1Q36315170-BBBB6963-2B4E-47A8-AD29-9A7C067C7676Q36361706-5A75B026-0ADF-4F6F-AD3D-8CAF7C18FDB9Q36427561-1A33F1BF-DAFE-4E05-A126-134DCEF1EA70Q36490806-2C89E73E-825C-48E5-927B-12587DF90CCEQ36520539-8084831B-F310-40AC-BFE9-BE94E84D0711Q36672809-A68B53BE-1F6A-449B-920D-2061F3A14C5AQ36719711-A88AEA14-8E9C-4938-ADA1-02D1B33FA1C6Q36728831-255D7D01-5A11-4B8D-A997-A4A2D9F95FEFQ36756965-4F9C7B60-8831-4ABA-856D-9166B3668317Q36806074-67194DC1-2110-4A61-9D8F-B1EC36631151Q36843454-51149FB2-2298-470F-8061-4988130EA478Q36866123-4DF8282D-99C7-45FC-8EEF-DFA720B63971Q36874598-6A415D23-5FF5-4173-BD4F-B5E8243DD423Q37024510-88DB2363-C6E7-4272-B6A5-B6104EB5F5DDQ37048192-6A8AB958-64E3-462F-8986-6DB8B7C1F012Q37086178-09A662AE-8C96-4DD0-A6E7-B39CE60E7EB5
P50
name
Mack Roach
@en
Mack Roach
@nl
type
label
Mack Roach
@en
Mack Roach
@nl
prefLabel
Mack Roach
@en
Mack Roach
@nl